Quan H, Ghali W A, Verhoef M J, Norris C M, Galbraith P D, Knudtson M L
Department of Community Health Sciences. University of Calgary, Calgary, Alberta, Canada.
Am J Med. 2001 Dec 15;111(9):686-91. doi: 10.1016/s0002-9343(01)00999-8.
Among patients who had undergone coronary angiography, we sought to determine the proportion of chelation therapy users, their sociodemographic and clinical characteristics, and the association of chelation therapy with subsequent revascularization.
We studied all patients who underwent coronary angiography in the province of Alberta, Canada, during 1995 and 1996. The cohort was followed for up to 6 years to determine subsequent revascularization status. Use of chelation therapy was determined by a mailed survey 1 year after angiography.
Among the 5854 patients who responded to the mail survey (70% response rate), 210 (3.6%) reported current use of chelation therapy and 252 (4.3%) reported past use. Current use of chelation therapy was associated with extensive coronary artery disease (adjusted odds ratio [OR] = 3.3; 95% confidence interval [CI]: 1.9 to 5.7 for 3-vessel disease; and OR = 2.7; 95% CI: 1.2 to 6.0 for left main disease, as compared with those with normal anatomy) and the absence of diabetes (OR = 0.6; 95% CI: 0.4 to 0.9). Current users were less likely to have undergone percutaneous transluminal coronary angioplasty (OR = 0.7; 95% CI: 0.5 to 0.9) and coronary artery bypass graft (CABG) surgery (OR = 0.3; 95% CI: 0.2 to 0.5) in the first year after angiography, but were as likely as nonusers of chelation therapy to have undergone CABG surgery in the subsequent 3- to 5-year period (adjusted hazard ratio [HR] = 1.1; 95% CI: 0.7 to 1.9). Past use of chelation therapy was associated with a history of CABG surgery before coronary angiography (OR = 1.6; 95% CI: 1.1 to 2.3) and extensive coronary artery disease. Past users were also more likely to have undergone CABG surgery in the follow-up period (HR = 1.7; 95% CI: 1.1 to 2.6).
About 8% of patients who underwent cardiac catheterization for coronary artery disease were using or had previously tried chelation therapy. Users may have foregone revascularization in favor of this less invasive yet unproven treatment, with some users subsequently undergoing conventional treatment after chelation. Alternatively, some patients may have turned to chelation as a "last resort" after having been judged unsuitable for revascularization.
在接受过冠状动脉造影的患者中,我们试图确定使用螯合疗法的患者比例、他们的社会人口统计学和临床特征,以及螯合疗法与后续血运重建的关联。
我们研究了1995年和1996年在加拿大艾伯塔省接受冠状动脉造影的所有患者。对该队列进行了长达6年的随访,以确定后续血运重建状态。螯合疗法的使用情况通过造影术后1年的邮寄调查来确定。
在回复邮寄调查的5854名患者中(回复率为70%),210名(3.6%)报告目前正在使用螯合疗法,252名(4.3%)报告过去使用过。目前使用螯合疗法与广泛冠状动脉疾病相关(校正比值比[OR]=3.3;三支血管病变的95%置信区间[CI]:1.9至5.7;左主干病变的OR=2.7;95%CI:1.2至6.0,与解剖结构正常者相比)以及无糖尿病(OR=0.6;95%CI:0.4至0.9)。目前使用者在造影术后第一年接受经皮冠状动脉腔内血管成形术(OR=0.7;95%CI:0.5至0.9)和冠状动脉旁路移植术(CABG)手术(OR=0.3;95%CI:0.2至0.5)的可能性较小,但在随后的3至5年期间接受CABG手术的可能性与未使用螯合疗法者相同(校正风险比[HR]=1.1;95%CI:0.7至1.9)。过去使用螯合疗法与冠状动脉造影前有CABG手术史(OR=1.6;95%CI:1.1至2.3)和广泛冠状动脉疾病相关。过去使用者在随访期间也更有可能接受CABG手术(HR=1.7;95%CI:1.1至2.6)。
因冠状动脉疾病接受心导管检查的患者中约8%正在使用或曾尝试过螯合疗法。使用者可能放弃了血运重建而选择这种侵入性较小但未经证实的治疗方法,一些使用者在螯合治疗后随后接受了传统治疗。或者,一些患者在被判定不适合血运重建后可能将螯合疗法作为“最后手段”。